AKI occurred in 34% of patients, but there were no differences between the two groups in the incidence or severity of AKI, increases in AKI biomarkers (cystatin C and neutrophil gelatinase-associated lipocalin) or increases in markers of inflammation (interleukin-6 and myeloperoxidase). Here, MPO is linked to acute kidney injury.